BIRC5 and neuroblastoma: Finally, troglitazone, an anti-hyperglycemic and anti-inflammatory drug used in the management of type 2 diabetes, has been shown to reduce expression of both cFLIP and Survivin, resulting in TRAIL sensitisation in neuroblastoma cells [150].